CERS vs HAE vs NTRA vs BAX

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -2. 0% for Haemonetics Corporation (HAE). Haemonetics Corporation (HAE) offers the better valuation at 26. 5x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Cerus Corporation (CERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Baxter International Inc.

is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus CERS's -54. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haemonetics Corporation (HAE) is the lower-risk stock at 0.

48β versus Cerus Corporation's 2. 13β — meaning CERS is approximately 347% more volatile than HAE relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -2. 0% for Haemonetics Corporation (HAE). On earnings-per-share growth, the picture is similar: Cerus Corporation grew EPS 25. 5% year-over-year, compared to -38. 1% for Haemonetics Corporation. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haemonetics Corporation (HAE) is the more profitable company, earning 7.

3% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 7. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HAE leads at 11. 7% versus -17. 6% for CERS. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Baxter International Inc.

(BAX) trades at 9. 2x forward P/E versus 11. 0x for Haemonetics Corporation — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HAE: 55. 6% to $84. 60.

In this comparison, BAX (3.

9% yield) pays a dividend. CERS, HAE, NTRA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haemonetics Corporation (HAE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

48)). Cerus Corporation (CERS) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HAE: +99. 2%, CERS: -54. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CERS is a small-cap quality compounder stock; HAE is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; BAX is a small-cap income-oriented stock. BAX pays a dividend while CERS, HAE, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.